https://kstockbriefing.com
![[Disclosure] Samsung Biologics (207940) – (Correction) Sales / Supply Contract / 2024-03-06](https://kstockbriefing.com/wp-content/uploads/2026/07/포맷변환-삼성바이오로직스.jpg)
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has expanded its pharmaceutical contract manufacturing agreement with UCB, increasing the contract value by KRW 381.9B from KRW 45.1B to KRW 427.0B, while disclosing the counterparty and contract end date (2030-12-31). 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint)…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has submitted its FY2023 Audit Report, receiving an ‘Unqualified’ opinion from Samil PricewaterhouseCoopers for its consolidated revenue of KRW 3.69T and operating profit of KRW 1.11T. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Shareholder Approval…
Read More “[Disclosure] Samsung Biologics (207940) – Submission of Audit Report / 2024-02-28” »
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has corrected its Audit Report Submission disclosure to rectify the receipt date (from 2023 to 2024), confirming an ‘Unqualified’ audit opinion from its external auditor for FY2023 consolidated revenue of KRW 3.69T and operating profit of KRW 1.11T. 📊 [Key Disclosure Details & Financial…
![[Disclosure] ALTEOGEN (196170) – Holding of Investor Relations (IR) Session / 2024-02-26](https://kstockbriefing.com/wp-content/uploads/2026/08/포맷변환알테오젠.jpg)
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen will participate in the “2024 K-Bio Insight Forum” held at Lotte Hotel Jeju from March 6 to March 8, 2024, to present its pipeline progress and conduct Q&A sessions for domestic and international healthcare industry participants and institutional investors. 📊 [Key Disclosure Details & Financial…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has submitted a corrected disclosure for its Annual General Meeting of Shareholders scheduled for March 15, 2024, adding agenda items for the new appointment of Seung-Hwan Suh as Outside Director and Audit Committee Member. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has confirmed that the Seoul Central District Prosecutors’ Office filed an appeal against the first-instance acquittal regarding embezzlement and malfeasance charges. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring Legal Proceedings Following Prosecution Appeal This disclosure reports…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has resolved to hold its 13th Annual General Meeting of Shareholders on March 15, 2024, to submit agenda items including the approval of FY2023 financial statements and the approval of the limit on director remuneration. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has submitted a corrected disclosure following receipt of the written judgment, adding detailed specifics on its first-instance acquittal regarding alleged accounting standards violations for FY2014 and FY2015. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring Prosecution Appeal…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed that it confirmed an appeal filed by the Seoul Central District Prosecutors’ Office against the first-instance acquittal on charges of accounting standards violations. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring Legal Proceedings and Final…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed that it was acquitted by the Seoul Central District Court in its first-instance trial regarding alleged accounting standards violations. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Tracking Correction Disclosure Upon Receiving Written Judgment and Potential…